Exerts protective effects on brain infarction, heart cell injury due to hypoxia and hypoglycemia and lowers serum CPK activity.
Biochem/physiol Actions
Selective thromboxane A2 receptor antagonist
Features and Benefits
This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
In normal rat liver, anaphylatoxin C5a induces glucose output from hepatocytes indirectly via prostanoids released from Kupffer cells. Correspondingly, it was found that hepatocytes, in contrast to Kupffer cells, did not express C5a receptors. Lipopolysaccharide (LPS) has been reported to
Journal of cardiovascular pharmacology, 41(3), 481-488 (2003-02-27)
The purpose of the current study was to compare the efficacy of two structurally unrelated thromboxane A (TXA ) receptor antagonists, KT2-962 and daltroban (BM 13.505), in a dog model of myocardial ischemia/reperfusion injury. Pentobarbital-anesthetized dogs were subjected to left
Laboratory investigation; a journal of technical methods and pathology, 83(12), 1733-1741 (2003-12-24)
Various inflammatory stimuli such as anaphylatoxin C5a, zymosan, and lipopolysaccharides (LPSs) have been reported both to enhance glucose output in the perfused rat liver and to induce prostanoid (ie, prostaglandin and thromboxane) release from Kupffer cells, the resident liver macrophages.
The American journal of physiology, 268(5 Pt 2), H1954-H1958 (1995-05-01)
The effects of platelet-activating factor (PAF) on vascular resistance and capillary permeability were studied in the isolated rat hindquarter. Six groups were studied (n = 30): control; PAF alone (1.4 microM); and PAF (1.4 microM) pretreated with ibuprofen (30 mg/kg)
Naunyn-Schmiedeberg's archives of pharmacology, 356(4), 462-466 (1998-01-24)
We sought to determine whether the intrinsic pulmonary hypertensive activity of the purported thromboxane A2/prostanoid (TP) receptor antagonist, daltroban, was mediated by TP receptors, using the high efficacy TP receptor agonist, U-46619, and the silent TP receptor antagonist, SQ 29,548.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
